Terminated NA INTERVENTIONAL 1-arm NCT00038818

CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

CD8 Depleted Donor Lymphocyte Infusions for Patients With Relapse Or Residual Disease Following Allogeneic Stem Cell Transplantation

Sponsor: Eligix

Conditions Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia Hodgkin's Disease Multiple Myeloma Non Hodgkin's Lymphoma

Interventions CD8 Depleted Donor Lymphocyte

Updated 6 times since 2017 Last updated: Aug 22, 2012 Started: May 31, 2001 Primary completion: Dec 31, 2002 Completion: Dec 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual.

Other Chronic Lymphocytic Leukemia trials with similar outcome

Browse all Chronic Lymphocytic Leukemia trials

A NA clinical study on Chronic Lymphocytic Leukemia and Chronic Myelogenous Leukemia, this trial is terminated or withdrawn. The trial is conducted by Eligix and has accumulated 6 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2021 — Jul 2024 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA
Feb 2017 — Jun 2018 [monthly]

Terminated NA

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

May 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eligix
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States